Co-Founder & CEO
Dr. Athanasiou is a proven leader in directing a range of cutting-edge research projects and advancing their outcomes toward clinical application. Dr. Athanasiou is a seasoned corporate pharma/biotech executive, having led interdisciplinary teams for the development of therapeutics and diagnostics. Her successes include the development of an FDA-approved drug, Vybrid (vilazodone), as well as the first commercially available pharmacogenetic test in psychiatry, managing a $100 million budget, and operating within aggressive timelines. Early career highlights include authorship on the groundbreaking Human Genome Sequencing Project published in Nature in 2001. Dr. Athanasiou cultivates strong relationships among numerous scientists, physicians, business executives, and manufacturers. Earning 13 patent applications and authoring numerous peer-reviewed publications, Dr. Athanasiou’s track record of leading projects through collaborative endeavors is the key to MarPam Pharma’s success in generating biologic therapeutics for the treatment of human disease.